Stoke Therapeutics (STOK) Receivables (2024 - 2026)

Stoke Therapeutics has reported Receivables for 3 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (changed N/A YoY), and the FY2025 full-year result was $7.9 million, up 233.83% from the prior year.
• Receivables for Q1 2026 stood at $6.1 million, down from $7.9 million in the prior quarter.
• The five-year high for Receivables was $10.8 million in Q3 2025, with the low at $2.4 million in Q4 2024.
• Average Receivables over 3 years is $6.8 million, with a median of $7.0 million recorded in 2025.
• Peak annual rise in Receivables reached 233.83% in 2025, while the deepest fall reached 233.83% in 2025.
• Tracing STOK's Receivables over 3 years: stood at $2.4 million in 2024, then surged by 233.83% to $7.9 million in 2025, then declined by 22.31% to $6.1 million in 2026.
• The last three Receivables figures came in at $6.1 million (Q1 2026), $7.9 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.

Peer Comparison